Biotech | February 18, 2022
USFDA clears Kairos Pharma’s IND to treat prostrate cancer
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Subscribe To Our Newsletter & Stay Updated